Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACM Research Inc (ACMR) vs Nuwellis Inc (NUWE) Price & Performance

ACM Research Inc
Nuwellis Inc

Price performance

Price movement over the last 24 hours

Key statistics

ACM Research Inc vs Nuwellis Inc — how do they compare? ACM Research Inc trades at $97.57 (market cap $6.54B), while Nuwellis Inc trades at $2.81 (market cap $1.15M). The key difference: ACM Research Inc is far larger — about 5687× Nuwellis Inc's market cap, and ACM Research Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.

ACMRNUWE
Market Cap
$6.54B$1.15M
Sector
TechnologyTechnology
52-Week High
$126.89$558.26
52-Week Low
$23.92$3.05
Enterprise Value
$5.61B-$662.47K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACM Research Inc

ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).

Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.

Nuwellis Inc

NUWE trades at $3.29, up 4.44% today, but faces a bearish technical outlook with moving averages signaling a downtrend. The company reported a net loss of $17.52 million in 2025, with a negative net income margin of -217.22%, though it beat earnings expectations in two of the last three quarters. Recent news highlights expansion efforts, including new CEO Mike McCormick outlining strategic priorities and a $6 million public offering closed in June 2026 to support growth.

The outlook remains challenging due to persistent losses and high cash burn, but low valuation ratios like a P/E of 0.64 and P/B of 0.45 may attract value investors. Key risks include the need to achieve profitability and competitive pressures in the medical technology sector. Analyst sentiment is mixed with a 50% buy rating, suggesting cautious optimism amid fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACM Research Inc

ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.

Read more on ACMR

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE